benzyloxycarbonyltyrosylalanine diazomethane: a cathepsin B inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 164025 |
| MeSH ID | M0161463 |
| Synonym |
|---|
| 117176-50-8 |
| benzyloxycarbonyltyrosylalanine diazomethane |
| n-benzyloxycarbonyltyrosylalanyldiazomethane |
| z-tyr-ala-chn2 |
| benzyloxycarbonyltyrosylalanyldiazomethane |
| carbamic acid, (2-((3-diazo-1-methyl-2-oxopropyl)amino)-1-((4-hydroxyphenyl)methyl)-2-oxoethyl)-, phenylmethyl ester |
| benzyl n-[1-[(4-diazo-3-oxobutan-2-yl)amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]carbamate |
| (z)-1-diazonio-3-[[3-(4-hydroxyphenyl)-2-phenylmethoxycarbonylamino-pr opanoyl]amino]but-1-en-2-olat |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (45.45) | 18.7374 |
| 1990's | 6 (54.55) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.00) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||